

CA OPIOID SETTLEMENTS
EXPENDITURE REPORTING FORM

SFY 2023 - 2024

**Prepared on 2025-12-04 by the University of
California, Los Angeles**

Integrated Substance Use and Addictions Programs



CONTENTS

GENERAL INFORMATION	1
CA ABATEMENT ACCOUNT FUNDS INFORMATION	1
CA Abatement Payments:	1
CA Abatement Reallocations:	2
CA Abatement Expenditures:	2
Activity#1	2
Activity#2	4
Activity#3	5
CA SUBDIVISION FUND INFORMATION	7
CA Subdivision Fund Payments:	7
CA Subdivision Fund Reallocations:	8
CA Subdivision Fund Future Opioid-Related Expenditures:	8
Activity#1	9
Activity#2	9
Activity#3	10
CA Subdivision Fund Reimbursements & Past Legal Expenses:	10
MALLINCKRODT BANKRUPTCY (NOAT II) FUND INFORMATION	10

Mallinckrodt Bankruptcy Payments:	11
Mallinckrodt Reallocations:	11
Mallinckrodt Allowable Expenses:	11
SUMMARY	12

GENERAL INFORMATION

Participating Subdivision: Humboldt County
Subdivision Department/Organization: DHHS-Department of Health and Human Services
Subdivision address: 825 5th Street Eureka California 95501
Name of Preparer: Susany Mendonca-Gupton
Preparer Title: Accountant Auditor II
Preparer Email Address: smendoncagupton@co.humboldt.ca.us
Preparer Phone Number: 707-441-5546
This Subdivision received funds from:
Settlements & Mallinckrodt Pharmaceuticals Bankruptcy

CA ABATEMENT ACCOUNT FUNDS INFORMATION

- Settlement(s):**
- Distributors (McKesson, Cardinal Health and Cencora, previously Amerisource Bergen)
 - Janssen Pharmaceuticals, Inc.

CA Abatement Payments:

Payments Received by this Subdivision from the CA Abatement Account Fund

Settlement	CA Abatement Account Payments Received in SFY 23-24
Distributors	\$784,006.43
Janssen	\$372,905.00

Is your Participating Subdivision depositing CA Abatement Accounts Fund payments from the National Settlement Administrator (Brown-Greer, PLC) into an interest-bearing account?: Yes

Interest Earned from the CA Abatement Account Fund

Settlement	CA Abatement Account Interest Earned in SFY 23-24
Distributors	\$0.00
Janssen	\$0.00

CA Abatement Reallocations:

Reallocations Sent: No funds received from the CA Abatement Account were reallocated to another Subdivision.

Reallocations Received: No funds received from the CA Abatement Account were reallocated from another Subdivision.

CA Abatement Expenditures:

How many total activities or programs funded by the funds from the CA Abatement Accounts Fund will you be reporting on for the SFY 23-24 (period of July 1, 2023 - June 30, 2024)?: 3

Activity#1

Activity or Program Name: Drug Medi-Cal Organized Delivery System Medi-Cal Match

Activity or Program Description: To support treatment for Medi-Cal patients served through the Drug Medi-Cal Organized Delivery System, experiencing homelessness at intake, qualifying as a High Impact Activity #3.

Expenditures reported were expended towards homeless population, with-
ing Humboldt County DMC-ODS Program, during fiscal year 2023-24.

Activity Costs and Encumbered Funds

Settlement	Direct Costs in SFY 23-24	Indirect Costs (Admin. Expenses) in SFY 23-24	Funds Encumbered in SFY 23-24
Distributors	\$501,996.87	\$4,675.63	\$0.00
Janssen	\$372,905.00	\$0.00	\$0.00

Did you previously encumber funds for this activity in SFY 22-23 that were not expended in SFY 23-24?: No

Activity Start Date (mm/dd/yyyy): 07/01/2023

All local agencies or organizations who were given funds during SFY 23-24 to implement this activity:

N/A

Allowable Expenditure Category: Treat Opioid Use Disorder (OUD)

High Impact Abatement Activity (HIAA) Category

HIAA Satisfied	Reasoning
<p>HIAA 3: Addressing the needs of communities of color and vulnerable populations (including sheltered and unsheltered homeless populations) that are disproportionately impacted by SUD Please describe, including the populations this activity or program serves:</p>	<p>To support treatment for Medi-Cal patients served through the Drug Medi-Cal Organized Delivery System, experiencing homelessness at intake, qualifying as a High Impact Activity #3. Expenditures reported were expended towards homeless population, withing Humboldt County DMC-ODS Program, during fiscal year 2023-24.</p>

Activity#2

Activity or Program Name: Interventions to prevent drug addiction in vulnerable youth

Activity or Program Description: Funding will support personnel costs for county Public Health outreach and evidence-informed prevention activities in schools throughout the county, prioritizing high-risk school. Supporting community coalitions in implementing evidence-informed prevention, such as reduced social access and physical access, stigma reduction—including staffing, educational campaigns, support for people in treatment or recovery, or training of coalitions in evidence-informed implementation, including the Strategic Prevention Framework developed by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA). Support prevention. Funding evidence-based prevention programs in schools or evidence-informed school and community education programs and campaigns for students, families, school employees, school athletic programs, parent-teacher and student associations, and others. School-based or youth-focused programs or strategies that have demonstrated effectiveness in preventing drug misuse and seem likely to be

effective in preventing the uptake and use of opioids. Create or support community-based education or intervention services for families, youth, and adolescents at risk for OUD and any co-occurring SUD/MH conditions.

Activity Costs and Encumbered Funds

Settlement	Direct Costs in SFY 23-24	Indirect Costs (Admin. Expenses) in SFY 23-24	Funds Encumbered in SFY 23-24
Distributors	\$11,800.00	\$96.05	\$0.00
Janssen	\$0.00	\$0.00	\$0.00

Did you previously encumber funds for this activity in SFY 22-23 that were not expended in SFY 23-24?: No

Activity Start Date (mm/dd/yyyy): 07/01/2023

All local agencies or organizations who were given funds during SFY 23-24 to implement this activity:

N/A

Allowable Expenditure Category: Prevent Misuse of Opioids

This activity does not meet the criteria to be a High Impact Abatement Activity.

Activity#3

Activity or Program Name: Medication Assisted Treatment in Jail

Activity or Program Description: OSF was used to increase nursing staffing in the Humboldt County jail from 2 to 12 hours per week, which expanded MAT suboxone treatment from 25 inmates to 100. Inmates are selected for the program by (1) if they are currently on Suboxone when they arrive at the jail, the program will continue their Suboxone after evaluation (2) inmates are screened using a WellPath scoring tool and Suboxone is inducted if indicated by the tool; (3) inmates may request the program

and WellPath will evaluate their OUD and, if qualified, put them on the program.

Activity Costs and Encumbered Funds

Settlement	Direct Costs in SFY 23-24	Indirect Costs (Admin. Expenses) in SFY 23-24	Funds Encumbered in SFY 23-24
Distributors	\$282,009.56	\$2,383.42	\$0.00
Janssen	\$0.00	\$0.00	\$0.00

Did you previously encumber funds for this activity in SFY 22-23 that were not expended in SFY 23-24?: No

Activity Start Date (mm/dd/yyyy): 07/01/2023

All local agencies or organizations who were given funds during SFY 23-24 to implement this activity:

N/A

Allowable Expenditure Category: Address the Needs of Criminal Justice-Involved Persons

High Impact Abatement Activity (HIAA) Category

HIAA Satisfied	Reasoning
HIAA 2: Creating new or expanded Substance Use Disorder (SUD) treatment infrastructure Please describe:	OSF was used to increase nursing staffing in the Humboldt County jail from 2 to 12 hours per week, which expanded MAT suboxone treatment from 25 inmates to 100. Inmates are selected for the program by (1) if they are currently on Suboxone when they arrive at the jail, the program will continue their Suboxone after evaluation (2) inmates are screened using a WellPath scoring tool and Suboxone is inducted if indicated by the tool; (3) inmates may request the program and WellPath will evaluate their OUD and, if qualified, put them on the program.

CA SUBDIVISION FUND INFORMATION

Is your Participating Subdivision also a Plaintiff Subdivision?: Yes

- Distributors (McKesson, Cardinal Health and Cencora, previously Amerisource Bergen)
- Janssen Pharmaceuticals, Inc.

CA Subdivision Fund Payments:

Payments Received by this Plaintiff Subdivision from the CA Subdivision Fund

Settlement	CA Subdivision Fund Payments Received in SFY 23-24
Distributors	\$57,090.25
Janssen	\$25,792.84

Is your Participating Subdivision depositing CA Subdivision Fund payments from the National Settlement Administrator (BrownGreer, PLC) into an interest-bearing account?: Yes

Interest Earned from the CA Subdivision Fund

Settlement	CA Subdivision Fund Interest Earned in SFY 23-24
Distributors	\$0.00
Janssen	\$0.00

CA Subdivision Fund Reallocations:

Reallocations Sent: No funds received from the CA Subdivision Fund were reallocated to another Subdivision.

Reallocations Received: No funds received from the CA Subdivision Fund were reallocated from another Subdivision.

CA Subdivision Fund Future Opioid-Related Expenditures:

How many total activities or programs were funded by funds from the CA Subdivision Fund will you be reporting on for the SFY 23-24 (period of July 1, 2023 - June 30, 2024)?: 3

Activity#1

Activity or Program Name: Drug Medi-Cal Organized Delivery System
Medi-Cal Match

Activity or Program Description: Funding will support OUD treatment for Medi-Cal patients served through the Drug Medi-Cal Organized Delivery System are experiencing homelessness at intake. The remaining funds qualify as evidence-based treatment in the ASAM continuum of care.

Activity Expenditures

Settlement	Funds Expended (SFY 23-24)
Distributors	\$36,554.71
Janssen	\$25,792.84

Allowable Expenditure Category:

2 – Treat or mitigate opioid use or related disorders.

Activity#2

Activity or Program Name: Medication Assisted Treatment in Jail

Activity or Program Description: Funding will support Medication Assisted Treatment delivery inside jail for inmates with OUD.

Activity Expenditures

Settlement	Funds Expended (SFY 23-24)
Distributors	\$10,802.92
Janssen	\$0.00

Allowable Expenditure Category:

2 – Treat or mitigate opioid use or related disorders.

Activity#3

Activity or Program Name: RxSafe Humboldt, local overdose safety coalition.

Activity or Program Description: Funding will support the local opioid community coalition "RxSafe Humboldt" including training and disseminating information to the public, families, schools and providers on safe prescribing, medication disposal, alternative pain management, naloxone distribution, and OUD treatment options.

Activity Expenditures

Settlement	Funds Expended (SFY 23-24)
Distributors	\$9,732.62
Janssen	\$0.00

Allowable Expenditure Category:

1 – Address the misuse and abuse of opioid products.

CA Subdivision Fund Reimbursements & Past Legal Expenses:

During SFY 23-24, did your Plaintiff Subdivision use settlement funds to cover past legal expenses related to opioid litigation?: No

During SFY 23-24, did your Plaintiff Subdivision use settlement funds to cover reimbursements for past opioid-related expenses spent prior to the receipt of settlement funds?: No

MALLINCKRODT BANKRUPTCY (NOAT II) FUND INFORMATION

Did your Local Government receive funds from the Mallinckrodt Bankruptcy (NOAT II)?: Yes

Mallinckrodt Bankruptcy Payments:

Total amount of funds received from NOAT II from July 1, 2023 – June 30, 2024:

\$109,374.00

Is your Local Government depositing Mallinckrodt Bankruptcy payments from NOAT II into an interest-bearing account?

Yes

Total amount of Interest earned from NOAT II from July 1, 2023 – June 30, 2024:

\$0.00

Mallinckrodt Reallocations:

Reallocations Sent:

No funds received from the Mallinckrodt Bankruptcy Funds were reallocated to another Subdivision.

Reallocations Received:

No funds received from the Mallinckrodt Bankruptcy Funds were reallocated from another Subdivision.

Mallinckrodt Allowable Expenses:

Did your Local Government expend any bankruptcy funds during the period of July 1, 2023 – June 30, 2024?: Yes

Mallinckrodt Allowable Expenses Breakdown

Approved Category	Direct Costs July - Dec. 2023	Direct Costs Jan. - June 2024	Indirect Costs July - Dec. 2023	Indirect Costs Jan - June 2024
Schedule B.A. Treat Opioid Use Disorder	\$0.00	\$70,375.58	\$0.00	\$3,518.78
Schedule B.H. Prevent Overdose Deaths and Other Harms (Harm Reduction)	\$3,981.86	\$15,858.00	\$32.41	\$136.50
Schedule B.G. Prevent Misuse of Opioids	\$1,128.60	\$14,138.78	\$15.04	\$188.45

SUMMARY

All tables below are based on information reported during the SFY 2023-24 only.

CA Abatement Account Fund Totals

Settlement	Payment	Interest	Reallocations Sent	Reallocations Received
Distributors	\$784,006.43	\$0.00	\$0.00	\$0.00
Janssen	\$372,905.00	\$0.00	\$0.00	\$0.00
Total	\$1,156,911.43	\$0.00	\$0.00	\$0.00

CA Abatement Account Activity Expenses

Settlement	Activity Expenses	Indirect Costs	23/24 Encumbered Funds	22/23 Encumbered Funds
Distributors	\$795,806.43	\$7,155.10	\$0.00	\$0.00
Janssen	\$372,905.00	\$0.00	\$0.00	\$0.00
Total	\$1,168,711.43	\$7,155.10	\$0.00	\$0.00

CA Subdivision Fund Totals

Settlement	Payment	Interest	Reallocation Sent	Reallocation Received
Distributors	\$57,090.25	\$0.00	\$0.00	\$0.00
Janssen	\$25,792.84	\$0.00	\$0.00	\$0.00
Total	\$82,883.09	\$0.00	\$0.00	\$0.00

CA Subdivision Fund Expenses

Settlement	Activity Expense	Legal Expenses	Reimbursed Activity Expense
Distributors	\$57,090.25	\$0.00	\$0.00
Janssen	\$25,792.84	\$0.00	\$0.00
Total	\$82,883.09	\$0.00	\$0.00

Mallinckrodt Bankruptcy (NOAT II) Fund Totals

Payment	Interest	Reallocations Sent	Reallocations Received
\$109,374.00	\$0.00	\$0.00	\$0.00

Mallinckrodt Bankruptcy (NOAT II) Fund Expenses

Direct Costs	Indirect Costs
\$105,482.82	\$3,891.18